Peter Young, Ph.D. is the Chief Scientific Officer at OrphAI Therapeutics. Dr. Young has over 25 years of experience in target identification, validation, drug discovery and development while holding various executive and management positions at SmithKline Beecham, DuPont Pharmaceuticals, SUGEN, Celera, Genelabs, Affymax and Resverlogix. He has worked in multiple therapeutic areas such as oncology, autoimmune/inflammation, hematology, metabolic and anti-viral disease and has contributed to the discovery and/or development of Promacta® for Idiopathic Thrombocytopenia Purpura, Imbruvica® for hematological cancer, Nucala® for severe eosinophilic asthma and several products in early clinical development, including apabetalone for atherosclerosis, abexinostat for lymphoma and a cathepsin S inhibitor for psoriasis. As VP Research at Affymax, Peter supported the CMC, translational, non-clinical safety and immunogenicity aspects of the development of Omontys®, a once a month pegylated peptidic erythropoietic agent, for the treatment of anemia. Peter is co-author on over 120 papers and co-inventor on 34 issued patents.